New immunotherapy drug tislelizumab targets Hard-to-Treat cancers

NCT ID NCT03736889

Recruiting now Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This Phase 2 trial is testing tislelizumab, an immunotherapy drug, in 200 people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR) and have not responded to prior treatments. The drug works by blocking PD-1, helping the immune system recognize and attack cancer cells. The main goal is to see how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab (an immunotherapy drug that helps the immune system attack cancer cells)
What this could lead to: If successful, this could offer a new treatment option for people with advanced cancers that have specific genetic features (MSI-H or dMMR) and have not responded to prior therapies.
What could go wrong: This is a mid-stage (Phase 2) trial with no control group, so results are preliminary. The drug may not work for all tumor types, and side effects from immune activation (e.g., inflammation of organs) are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lynch syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MSI-H/DMMR SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Affiliated Hospital of Hebei University
COMPLETED

Baoding, Hebei, 071000, China
Affiliated Zhongshan Hospital of Fudan University
COMPLETED

Shanghai, Shanghai Municipality, 200032, China
Anhui Provincial Hospital
COMPLETED

Hefei, Anhui, 230000, China
Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Beijing Cancer Hospital
ACTIVE_NOT_RECRUITING

Beijing, Beijing Municipality, 100142, China
Cancer Hospital Chinese Academy of Medical Sciences
COMPLETED

Beijing, Beijing Municipality, 100021, China
Chongqing University Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
Fudan University Shanghai Cancer Center
COMPLETED

Shanghai, Shanghai Municipality, 200000, China
Fujian Medical University Union Hospital
ACTIVE_NOT_RECRUITING

Fuzhou, Fujian, 350001, China
Guangdong Provincial Peoples Hospital
COMPLETED

Guangzhou, Guangdong, 510080, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150000, China
Henan Cancer Hospital
COMPLETED

Zhengzhou, Henan, 450000, China
Hubei Cancer Hospital
COMPLETED

Wuhan, Hubei, 430079, China
Huizhou First Hospital
RECRUITING

Huizhou, Guangdong, 516000, China
Hunan Cancer Hospital
COMPLETED

Changsha, Hunan, 410013, China
Jiangsu Province Hospital
COMPLETED

Nanjing, Jiangsu, 210029, China
Jilin Cancer Hospital
COMPLETED

Changchun, Jilin, 130021, China
Meizhou People Hospital
RECRUITING

Meizhou, Guangdong, 514031, China
Nanfang Hospital of Southern Medical University
COMPLETED

Guangzhou, Guangdong, 510515, China
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
COMPLETED

Nanjing, Jiangsu, 210008, China
The Affiliated Hospital of Military Medical Sciences
COMPLETED

Beijing, Beijing Municipality, 100071, China
The First Affiliated Hospital, Zhejiang University School of Medicine
COMPLETED

Hangzhou, Zhejiang, 310003, China
The First Peoples Hospital of Yibin
ACTIVE_NOT_RECRUITING

Yibin, Sichuan, 644000, China
The General Hospital of Shenyang Military
COMPLETED

Shenyang, Liaoning, 110016, China
The Peoples Hospital of Hechi
ACTIVE_NOT_RECRUITING

Hechi, Guangxi, 547099, China
The Sixth Affiliated Hospital, Sun Yat Sen University
COMPLETED

Guangzhou, Guangdong, 510655, China
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
COMPLETED

Wuhan, Hubei, 430030, China
Yidu Central Hospital of Weifang
COMPLETED

Weifang, Shandong, 262550, China
Zhejiang Cancer Hospital
COMPLETED

Hangzhou, Zhejiang, 310022, China
Zhejiang University College of Medicine Second Affiliated Hospital
COMPLETED

Hangzhou, Zhejiang, 310009, China